Hypothesis: Timed administration of a senolytic followed by an NAD+ precursor during the mTORC1‑suppressed autophagy window blocks CD38 induction in neighboring cells, thereby preventing NAD+ depletion and the propagation of secondary senescence.

Mechanistic rationale:

• Senolytic clearance of p16^INK4a^‑positive cells triggers a transient SASP burst that includes IL‑6 and IL‑1α, which can stimulate CD38 expression in nearby cells via JAK/STAT signaling [7]. CD38 consumes NAD+, lowering SIRT1 activity and reinforcing a senescent state.
• Intermittent rapamycin (or similar mTORC1 inhibitor) given 12‑24 h before senolytic dosing enhances autophagic flux, facilitating rapid removal of senescent debris and reducing the duration of SASP exposure [4]. This creates a narrow “clearance window” where extracellular SASP concentrations peak but are quickly attenuated.
• Supplementing with an NAD+ precursor (e.g., NMN) immediately after senolytic exposure raises intracellular NAD+ pools, competitively inhibiting CD38 enzymatic activity and preserving SIRT1‑mediated deacetylation of NF‑κB, thereby dampening further SASP production [6].
• The combined sequence (mTORC1 inhibition → senolytic → NAD+ booster) aligns with natural circadian cycles of catabolism and anabolism, mimicking the beneficial effects of fasting‑refeeding cycles on proteostasis [5].

Testable predictions:

1. In progeroid mice, the triple‑intervention (rapamycin → dasatinib+quercetin → NMN) will reduce CD38^+^ cell frequency in liver and adipose tissue by >40% compared with senolytic alone, measured by flow cytometry at 48 h post‑treatment [2].
2. NAD+ levels in tissues adjacent to cleared senescent zones will remain ≥80% of baseline, whereas senolytic‑only groups will show a 30‑50% drop [3].
3. SASP factor concentrations (IL‑6, IL‑1α) in plasma will peak earlier and return to baseline twice as fast in the triple group versus senolytic‑only, confirming accelerated SASP resolution [1].
4. Functional readouts (grip strength, treadmill endurance) will improve significantly only in the triple‑intervention cohort, indicating that preventing secondary senescence translates to physiological benefit.

Falsifiability: If CD38 upregulation persists despite NAD+ supplementation, or if NAD+ levels fall regardless of timing, the hypothesis is refuted. Likewise, if mTORC1 inhibition does not shorten SASP exposure, the proposed mechanistic link fails.

Implications: This protocol refines intermittent senolytic strategies by directly addressing a key unintended consequence of clearance—local NAD+ sabotage—thereby widening the therapeutic window and reducing the need for frequent dosing.